Leaders in Partnering, M&A Deals and Strategic Alliances
What We Do
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 28 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Asia-Pacific.
more about us
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fundraising, and expert testimonies)
Our Latest Video
Exploring the challenges faced by pharmaceutical companies during manufacturing divestments, and how to accelerate the divestment process to achieve a successful outcome.
Paul Larsmon spoke with leading experts including:
- Mark Bamforth, President and CEO, Arranta Bio
- Stéphane Lepeu, Directeur Général Délégué / Chief Commercial Officer, DELPHARM
- Jansen Jacob, Vice President, PharmaVentures
Facts About Us
Nearly 30 years of experience
Facts About Us
Clients in 38 countries
Facts About Us
Over 900 projects
Oxford, UK, 24th November 2020 PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting...
For the Latest Industry Information
We conducted a detailed assessment of the market opportunities, technology risks and developments, launch and marketing costs via scenarios of “go-it-alone”, “outright sale”, “out-licensing for royalties” as well as “out-licensing with co-promotion”. The value generated was modelled and the scenarios were prioritised. Partnering and deal strategies were developed for the selected optimal strategy and incorporated into a business plan.
PharmaVentures developed a customised search strategy based on the specific requirements of the client, which involved a systemic country by country identification of candidates with the correct therapeutic indications, combined with their commercial potential and availability for the territories of interest.
PharmaVentures conducted a compound valuation (bottom-up and benchmarking using PharmaDeals Agreements® data) providing the basis for future negotiations. We also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month our transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.
PharmaVentures’ Industry Insight: We predict that licensing and partnering activity will remain steady in 2020
As we all know deal making is the life and blood of the biopharma industry and today this activity is truer than ever. In my experience of thirty years in deal making, companies who were most active...
What Our Clients Say
“We hired PharmaVentures when our management team decided that as a matter of urgency, we needed to identify and secure products to replace a product line in the short term. Within a two-months-period, the excellent team at PV identified more than 60 product opportunities for us and initiated CDA’s and first contacts with the most interesting of them”